Skip to main content

Wave Life Sciences Ltd. (WVE) Stock Analysis

Recovery setup

SellHigh Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $7.08: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.9/10. Specifically: Elevated put/call ratio: 4.00; Below-average business quality; Rich valuation.

Wave Life Sciences is a clinical-stage RNA medicines company with lead programs WVE-007 (obesity, GalNAc siRNA), WVE-006 (AATD, RNA editing AIMer), WVE-008 (PNPLA3 I148M liver disease, RNA editing AIMer), plus clinical programs for DMD and Huntington disease. The company had an... Read more

$7.08+7.1% A.UpsideScore 3.9/10#152 of 158 Biotechnology
Stop $6.59Target $7.59(resistance)A.R:R 0.0:1
Analyst target$23.13+226.6%16 analysts
$7.59our TP
$7.08price
$23.13mean
$52

Sell if holding. Engine safety override at $7.08: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.9/10. Specifically: Elevated put/call ratio: 4.00; Below-average business quality; Rich valuation. Chart setup: Death cross but MACD improving, RSI 48. Score 3.9/10, high confidence.

Passes 3/6 gates (no SEC red flags, earnings proximity 90d clear, semi cycle peak clear). Fails on weak momentum and clean insider activity. Suitability: aggressive.

Val0.0Qual1.9Grw5.0Mom3.5Sent8.1Ins6.2Peer4.3Tech4.4Risk3.53.9OVERALL

Thesis

Rewards
No bull case signals
Risks
DATA_ISSUE: analyst_target_implausible (raw $23.12 vs price $7.08 — ratio 3.3×). Rejected, falling back to technical TP.
Quality below floor (1.9 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-6.3
Mkt Cap$1.4B
EV/EBITDA-4.3
Profit Mgn-255.7%
ROE-53.1%
Rev Growth316.9%
Beta-1.32
DividendNone
Rating analysts20

Quality Signals

Piotroski F3/9

Options Flow

P/C4.00bearish
IV64%elevated
Max Pain$4-43.5% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Ps
0.0
Expensive valuation
Low model confidence on this dimension (20%).

Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static

Roe
0.0
Roa
0.0
Operating Margin
0.0
Fcf Quality
0.0
Piotroski F
3.3
Current Ratio
5.0
Moat
5.0
Cash-burning: FCF -175% of revenueNo competitive moatWeak Piotroski F-Score: 3/9Quality concerns

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume
0.0
Obv
1.0
Ma Position
2.2
Rsi
4.5
Macd
9.7
Volume distribution (falling OBV)Below 200-MA but MA still rising (+1.4%/30d) — pullback in uptrend, not confirmed weakness
GatesMomentum 3.5<4.5INSIDER 3.97%=EXTREMEA.R:R UPSIDE_EXHAUSTED (upside=0.0%)No SEC red flagsEARNINGS PROXIMITY 90d clearSEMI CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
48 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $6.61Resistance $7.74

Price Targets

$7
$8
A.Upside+7.2%
A.R:R0.0:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! DATA_ISSUE: analyst_target_implausible (raw $23.12 vs price $7.08 — ratio 3.3×). Rejected, falling back to technical TP.
! Quality below floor (1.9 < 4.0)
! Momentum score 3.5/10 — below 4.5 minimum

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-07-29 (90d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is WVE stock a buy right now?

Sell if holding. Engine safety override at $7.08: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.9/10. Specifically: Elevated put/call ratio: 4.00; Below-average business quality; Rich valuation. Chart setup: Death cross but MACD improving, RSI 48. Prior stop was $6.59. Score 3.9/10, high confidence.

What is the WVE stock price target?

Take-profit target: $7.59 (+7.1% upside). Prior stop was $6.59. Stop-loss: $6.59.

What are the risks of investing in WVE?

DATA_ISSUE: analyst_target_implausible (raw $23.12 vs price $7.08 — ratio 3.3×). Rejected, falling back to technical TP.; Quality below floor (1.9 < 4.0).

Is WVE overvalued or undervalued?

Wave Life Sciences Ltd. trades at a P/E of N/A (forward -6.3). TrendMatrix value score: 0.0/10. Verdict: Sell.

What do analysts say about WVE?

20 analysts cover WVE with a consensus score of 4.3/5. Average price target: $23.

What does Wave Life Sciences Ltd. do?Wave Life Sciences is a clinical-stage RNA medicines company with lead programs WVE-007 (obesity, GalNAc siRNA),...

Wave Life Sciences is a clinical-stage RNA medicines company with lead programs WVE-007 (obesity, GalNAc siRNA), WVE-006 (AATD, RNA editing AIMer), WVE-008 (PNPLA3 I148M liver disease, RNA editing AIMer), plus clinical programs for DMD and Huntington disease. The company had an accumulated deficit of $1,326.2M as of December 31, 2025.

Related stocks: HRMY (Harmony Biosciences Holdings, I) · AUPH (Aurinia Pharmaceuticals Inc) · NVAX (Novavax, Inc.) · CPRX (Catalyst Pharmaceuticals, Inc.) · INVA (Innoviva, Inc.)